^
Association details:
| Biomarker: | EWSR1-WT1 fusion |
|---|---|
| Cancer: | Soft Tissue Sarcoma |
| Drug: | Yondelis (trabectedin) (Alkylating agent, DNA inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Trabectedin (T) in desmoplastic small round cell tumor (DSRCT): Report of its effect in 3 relapsed patients (pts) and the comparison of different regimens in a patient-derived xenograft (PDX) model
Published date:
05/19/2021
Excerpt:
Consistency of PDX and the originating tumor was confirmed in terms of histomorphology and presence of the EWS-WT1 gene fusion. Mice were randomized to receive D, P and T, administered as single agents...In the DSRCT PDX model, T was the most effective drug, with a maximum TVI of 82%...Both our preliminary model and our further clinical observations support the potential of T in DSRCT.
DOI:
10.1200/JCO.2021.39.15_suppl.e23553
